about
Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffeeSerum antibodies from Parkinson's disease patients react with neuronal membrane proteins from a mouse dopaminergic cell line and affect its dopamine expressionDiagnosis and treatment of dystoniaTemporal profile of improvement of tardive dystonia after globus pallidus deep brain stimulationCognitive profile of LRRK2-related Parkinson's diseaseOccupation and risk of parkinsonism: a multicenter case-control studyMeta-analysis of Parkinson's disease: identification of a novel locus, RIT2.β-Hexachlorocyclohexane levels in serum and risk of Parkinson's diseaseOccupational exposure to PCBs reduces striatal dopamine transporter densities only in women: a beta-CIT imaging studyCommon genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease.Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database.Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.A randomized, placebo-controlled trial of latrepirdine in Huntington disease.Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's diseaseAssociation analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease.SNCA variant associated with Parkinson disease and plasma alpha-synuclein level.Non-human primate FOG develops with advanced parkinsonism induced by MPTP Treatment.Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study.Tardive dyskinesia: therapeutic options for an increasingly common disorder.Identification of a novel Parkinson's disease locus via stratified genome-wide association studyPeople with Parkinson's disease and normal MMSE score have a broad range of cognitive performanceGBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.The natural history of the syndrome of primary progressive freezing gait.Identification of genetic modifiers of age-at-onset for familial Parkinson's diseaseDisentangling Stigma from Functional Neurological Disorders: Conference Report and Roadmap for the Future.Physiology of freezing of gait.Dystonia in AIDS: report of four cases.Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease.Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.Of monkeys and men: analysis of the phase 2 double-blind, sham-surgery controlled, randomized trial of AAV2-neurturin gene therapy for Parkinson's disease.Movement disorders emergencies. Part 1: Hypokinetic disorders.Internal consistency of the University of Michigan RBD QuestionnaireEvidence for more than one Parkinson's disease-associated variant within the HLA region.Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis.Parkinson's Disease: Initial Treatment with Levodopa or Dopamine Agonists.Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease.Tardive Syndromes are Rarely Reversible after Discontinuing Dopamine Receptor Blocking Agents: Experience from a University-based Movement Disorder Clinic.APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.Glutamate receptor gene GRIN2A, coffee, and Parkinson disease.
P50
Q21092426-2C17A743-C221-4348-9D4E-C8653E548B05Q25257546-167F35E7-C274-4F49-954A-A7082F2CE6A5Q26830473-F09AA720-C9DD-406A-B8FD-85E77F7655C0Q27304627-0D246216-24D3-484E-A3EA-418FF133F14DQ27333093-1F432CAC-DAD0-46AA-934C-F5E0B7E3B7C6Q28258493-550647C5-725A-4FB9-B338-36942924FE83Q28262863-9B8AD4F1-1C62-4829-951A-23785246DF62Q28392112-D85E211B-8A2C-4D24-9E68-7DB12C179FD5Q28394720-848E7013-5D0B-4985-B96C-39640270AFD4Q28943440-8585F41B-F9E7-457C-B128-D482DC73851DQ29417106-09B02CB8-4C9D-4514-A5E1-9CFD764CCBA8Q30278084-53541F72-B5E7-4DDE-8761-1AC438C10B25Q30411257-9805FB67-E1DD-4587-9A06-1532F62FC750Q30492462-A35DF201-5D0B-415E-BD6F-6558ADB68DA8Q30493604-02FA5C54-D6E1-4973-B9A3-9EC80F083E02Q30497763-220B3C8A-7B2A-443B-A17A-928A9790EF18Q30536650-563BF349-BAD6-45BA-948D-E8D6907C1CF3Q30539203-4880167A-EB10-4C76-B02E-052247103051Q30566749-CE1A7E3E-3173-4E4D-A799-E70F4006D07EQ30571934-1136B65C-153F-4924-A7C5-32B95DCD2B6CQ30586896-FB846849-4251-461A-B39B-49A31763885DQ30700188-2796214E-460B-4251-A36D-4E4FA3C8F515Q30746558-4B353FD1-34A4-47E4-A1A5-6E762F25E3CFQ30833988-D494FE6C-81FB-429B-BAD9-180451298B5BQ30843332-11E84A22-F7CE-4B83-A04D-50BB2EB0790AQ31131953-D818FD23-A360-41C3-9FB1-18DB9DFB77FDQ33195932-6C020EBC-7036-4401-943F-CC9AE12C3FD4Q33660426-383DC9BD-209B-43C6-AF9E-F1FF1619B924Q33714619-48D632DC-3AA8-4299-8A23-F603BA9FF16FQ33877296-5EB71B73-BC12-455E-AE25-741B9C0820D7Q33893617-A3682B22-F3E4-4438-BF3D-F2D1F983DC1DQ33911437-8CC9A44B-6E3A-4DC4-A4AB-7D5C28EE1E47Q34077754-C791D3FF-C79A-433C-AB03-EFEAE2CB5B9DQ34140991-23FC54AE-B58E-4C3E-8C8A-DD7A41886F02Q34388170-E252AEE7-3214-47D6-A19C-20A1FEF6C356Q34438073-D7AF7D2A-B600-44C5-9D4E-5FFA4354E224Q34447349-C156BDEA-E038-4994-8108-8644D806883FQ34490496-4207F3C1-E251-4461-AADC-7643ED27A5B9Q34492934-B9573A59-FC96-4F70-878D-97E15C22070EQ34549411-AC1FF068-6ADA-42D0-9D66-0AD8845A14E2
P50
description
onderzoeker
@nl
name
Stewart A Factor
@ast
Stewart A Factor
@en
Stewart A Factor
@es
Stewart A Factor
@nl
type
label
Stewart A Factor
@ast
Stewart A Factor
@en
Stewart A Factor
@es
Stewart A Factor
@nl
prefLabel
Stewart A Factor
@ast
Stewart A Factor
@en
Stewart A Factor
@es
Stewart A Factor
@nl
P1006
P214
P1006
P106
P214
P31
P4012
P569
1956-11-25T00:00:00Z
P7859
lccn-n2002133124